Item 16. FORM 10-K SUMMARY
3K characters. Original on sec.gov · Markdown
Item 16. FORM 10-K SUMMARY
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, West Pharmaceutical Services, Inc. has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
WEST PHARMACEUTICAL SERVICES, INC.
(Registrant)
By: /s/ Bernard J. Birkett
Bernard J. Birkett
Senior Vice President, Chief Financial and Operations Officer
February 21, 2023
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of West Pharmaceutical Services, Inc. and in the capacities and on the dates indicated.
| Signature | Title | Date | ||||||
| /s/ Eric M. Green | President, Chief Executive Officer and Chair of the Board | February 21, 2023 | ||||||
| Eric M. Green | (Principal Executive Officer) | |||||||
| /s/ Bernard J. Birkett | Senior Vice President, Chief Financial and Operations Officer | February 21, 2023 | ||||||
| Bernard J. Birkett | (Principal Financial Officer) | |||||||
| /s/ Chad R. Winters | Vice President, Chief Accounting Officer and Corporate Controller | February 21, 2023 | ||||||
| Chad R. Winters | (Principal Accounting Officer) | |||||||
| /s/ Mark A. Buthman | Director | February 21, 2023 | ||||||
| Mark A. Buthman | ||||||||
| /s/ William F. Feehery, Ph.D. | Director | February 21, 2023 | ||||||
| William F. Feehery, Ph.D. | ||||||||
| /s/ Robert F. Friel | Director | February 21, 2023 | ||||||
| Robert F. Friel | ||||||||
| /s/ Thomas W. Hofmann | Director | February 21, 2023 | ||||||
| Thomas W. Hofmann | ||||||||
| /s/ Molly E. Joseph | Director | February 21, 2023 | ||||||
| Molly E. Joseph | ||||||||
| /s/ Deborah L.V. Keller | Director | February 21, 2023 | ||||||
| Deborah L.V. Keller | ||||||||
| /s/ Myla P. Lai-Goldman, M.D. | Director | February 21, 2023 | ||||||
| Myla P. Lai-Goldman, M.D. | ||||||||
| /s/ Douglas A. Michels | Director | February 21, 2023 | ||||||
| Douglas A. Michels | ||||||||
| /s/ Paolo Pucci | Director | February 21, 2023 | ||||||
| Paolo Pucci | ||||||||
| /s/ Stephen Lockhart, Ph.D. | Director | February 21, 2023 | ||||||
| Stephen Lockhart, Ph.D. |
Previous: Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
Sponsor Sponsor this sector. One slot per industry, shown on every filing in it. Details